Moving on from a painful Phase II failure for its top prospect, Ohr Pharmaceutical heralded new hope for the eye drop in retinal vein occlusion thanks to some positive results from a midstage study. ...read more Source: Ohr rebounds from a costly failure with positive eye drop data
